Abstract:Background: After an acute coronary syndrome(ACS), patients continue to be at risk of major adverse cardiovascular events (MACE) despite the standard treatment. The risk of MACE may be secondary to thrombin, which remains elevated after ACS.We evaluated the safety and efficacy of the novel oral anticoagulant (NOAC), factor Xa inhibitor rivaroxaban. Methods: In our study, we randomly assigned 100 patients with a recent ACS to receive the once-daily dose of 2.5mg of rivaroxaban or placebo in addition to dual ant… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.